The Safety And Efficacy Of Maintenance Therapy With CP-690,550

NCT ID: NCT01393899

Last Updated: 2017-01-09

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-31

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo BID

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

oral tablets twice daily

5mg BID

Group Type EXPERIMENTAL

CP-690,550

Intervention Type DRUG

oral tablets twice daily

10mg BID

Group Type EXPERIMENTAL

CP-690,550

Intervention Type DRUG

oral tablets twice daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

oral tablets twice daily

Intervention Type DRUG

CP-690,550

oral tablets twice daily

Intervention Type DRUG

CP-690,550

oral tablets twice daily

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects who met study entry criteria, and who completed Week 8 visit of Induction Study A3921083.
* Subjects who achieve clinical response-100 (reduction in CDAI by 100 points) and/or clinical remission (CDAI\<150) in Study A3921083.
* Women of childbearing potential must test negative for pregnancy prior to study enrolment.

Exclusion Criteria

* Subjects who had major protocol violation (as determined by the Sponsor) in the A3921083 study.
* Subjects likely to require any type of surgery during the study period.
* Fecal culture/toxin assay indicating presence of pathogenic infection.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ACMG Endoscopy Center

Anaheim, California, United States

Site Status

ACRI - Phase I, LLC

Anaheim, California, United States

Site Status

Advanced Clinical Research Institute-Phase 1, LLC

Anaheim, California, United States

Site Status

West Coast Clinical Trials

Cypress, California, United States

Site Status

Alliance Clinical Research

Oceanside, California, United States

Site Status

Clinical Research Of The Rockies

Lafayette, Colorado, United States

Site Status

Gasteroenterology Consultants of Clearwater

Clearwater, Florida, United States

Site Status

West Coast Endoscopy Center

Clearwater, Florida, United States

Site Status

Clinical Research of West Florida, Inc.

Clearwater, Florida, United States

Site Status

Shands Endoscopy Center

Gainesville, Florida, United States

Site Status

Shands Hospital at the University of Florida

Gainesville, Florida, United States

Site Status

Shands Medical Plaza and Cancer Center

Gainesville, Florida, United States

Site Status

University of Florida - College of Medicine

Gainsville, Florida, United States

Site Status

Gastroenterology Group of Naples

Naples, Florida, United States

Site Status

Gulfshore Endoscopy Center (Endoscopies Only)

Naples, Florida, United States

Site Status

North Florida Gastroenterology Research, LLC

Orange Park, Florida, United States

Site Status

Internal Medicine Specialists

Orlando, Florida, United States

Site Status

Gastroenterology Associates of Central Georgia, LLC

Macon, Georgia, United States

Site Status

Cotton-O'Neil Clinical Research Center, Digestive Health

Topeka, Kansas, United States

Site Status

Chevy Chase Endoscopy Center

Chevy Chase, Maryland, United States

Site Status

Metropolitan Gastroenterology Group, PC

Chevy Chase, Maryland, United States

Site Status

East Ann Arbor Health and Geriatrics Center

Ann Arbor, Michigan, United States

Site Status

University of Michigan Health Systems

Ann Arbor, Michigan, United States

Site Status

Center for Digestive Health

Troy, Michigan, United States

Site Status

Surgical Centers of Michigan

Troy, Michigan, United States

Site Status

NYU Langone Nassau Gastroenterology Associates

Great Neck, New York, United States

Site Status

Premier Medical Group of the Hudson Valley, PC

Poughkeepsie, New York, United States

Site Status

Investigational Drug Services - University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

University Hospitals Case Medical Center

Cleveland, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Great Lakes Gastroenterology

Mentor, Ohio, United States

Site Status

Digestive Health Specialists of Tyler

Tyler, Texas, United States

Site Status

Endoscopy Center of Tyler

Tyler, Texas, United States

Site Status

University of Utah HSC

Salt Lake City, Utah, United States

Site Status

Cardiology Consultants

Norfolk, Virginia, United States

Site Status

Digestive & Liver Desease Specialists

Norfolk, Virginia, United States

Site Status

Metropolitan Gastroenterology Group, P C

Washington DC, Virginia, United States

Site Status

The Center for Digestive Health

Milwaukee, Wisconsin, United States

Site Status

Wisconsin Center for Advanced Research - GI Associates, LLC

Milwaukee, Wisconsin, United States

Site Status

Allegiance Research Specialists

Wauwatosa, Wisconsin, United States

Site Status

GI Associates

Wauwatosa, Wisconsin, United States

Site Status

Nepean Public Hospital

Kingswood, New South Wales, Australia

Site Status

Monash Medical Centre

Clayton, Victoria, Australia

Site Status

Royal Melbourne Hospital

Melbourne, , Australia

Site Status

AKH Wien Universitaetsklinik fuer Innere Medizin III

Vienna, , Austria

Site Status

4 MBAL Parvo vatreshno otdelenie

Sofia, , Bulgaria

Site Status

MBAL Sofiamed OOD, Otdelenie po gastroenterologia

Sofia, , Bulgaria

Site Status

Office of Dr. David C. Pearson

Victoria, British Columbia, Canada

Site Status

Office of Drs. Ranjith Andrew Singh and Jamie D. Papp,

Victoria, British Columbia, Canada

Site Status

PerCuro Clinical Research Ltd.

Victoria, British Columbia, Canada

Site Status

London Health Sciences Centre - University Hospital

London, Ontario, Canada

Site Status

Montreal General Hospital - McGill University Health Centre

Montreal, Quebec, Canada

Site Status

Hepato-Gastroenterologie HK, s.r.o.

Hradec Králové, , Czechia

Site Status

Medial Pharma spol.s.r.o. (Pharmacy only)

Hradec Králové, , Czechia

Site Status

RDG centrum s.r.o. (Radiology only)

Hradec Králové, , Czechia

Site Status

Hopital Huriez CHRU de Lille

Lille, , France

Site Status

Hôpital Haut-Lévêque/Service d hépato-gastroentérologie

Pessac, , France

Site Status

Charite - Campus Berlin Mitte

Berlin, , Germany

Site Status

Charite - Campus Benjamin Franklin

Berlin, , Germany

Site Status

Charite, Universitaetsmedizin Berlin, Campus Virchow-Klinikum

Berlin, , Germany

Site Status

Universitaetsklinikum Schleswig-Holstein

Kiel, , Germany

Site Status

Universitaetsklinikum Ulm, Klinik Fuer Innere Medizin I

Ulm, , Germany

Site Status

General Hospital of Athens "Evangelismos",1st Gastroenterology Department

Kolonaki Athens, , Greece

Site Status

Szent Janos Korhaz es Eszak-budai Egyesitett Korhazak/I. Belgyogyaszat es Gastroenterologia

Budapest, , Hungary

Site Status

Pannonia Magánorvosi Centrum Kft

Budapest, , Hungary

Site Status

Laboratorium Kft. Fovarosi és Pest Megyei Mikrobiologiai Laboratorium

Budapest, , Hungary

Site Status

Peterfy Sandor Utcai Korhaz, Rendelointezet es Baleseti Kozpont, I. sz. Belgyogyaszat

Budapest, , Hungary

Site Status

Bugat Pal Korhaz Egeszsegugyi Szolgaltato Kozhasznu Nonprofit Kft.,

Gyöngyös, , Hungary

Site Status

Laboratórium Kft. Somogy Megyei Mikrobiológiai Laboratórium

Kaposvár, , Hungary

Site Status

Clinfan Kft.

Szekszárd, , Hungary

Site Status

Digestive Disease Institute

Jerusalem, , Israel

Site Status

Meir Medical Center

Kfar Saba, , Israel

Site Status

Tel Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

The Hospital of Hyogo College of Medicine

Nishinomiya, Hyōgo, Japan

Site Status

National Hospital Organization Sendai Medical Center

Sendai, Miyagi, Japan

Site Status

Osaka City University Hospital

Osaka, Osaka, Japan

Site Status

Toho University Sakura Medical Center

Chiba, , Japan

Site Status

Hokkaido P.W.F.A.C Sapporo-Kosei general Hospital

Hokkaido, , Japan

Site Status

VU University Medical Center

Amsterdam, , Netherlands

Site Status

Academisch Medisch Centrum

Amsterdam, , Netherlands

Site Status

Kingsbury Hospital

Cape Town, Western Cape, South Africa

Site Status

Parklands Medical Centre

Durban, , South Africa

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Samsung Medical Center, Division of Gastroenterology, Department of Internal Medicine

Seoul, , South Korea

Site Status

ASAN Medical Center,Division of Gastroenterology,Department of Internal Medicine

Seoul, , South Korea

Site Status

Hospital Clinic de Barcelona

Barcelona, Barcelona, Spain

Site Status

Comite Etico de Investigacion Clinica

Barcelona, , Spain

Site Status

Hospital Universitario de La Princesa

Madrid, , Spain

Site Status

Donetsk National Medical University n.a M. Gorky, Faculty of Internal Medicine #2

Donetsk, , Ukraine

Site Status

Municipal Institution "Odesa Regional Clinical Hospital", Odesa Regional Centre of Gastroenterology.

Odesa, , Ukraine

Site Status

Medical Clinical Research Center of Medical Center "Health Clinic" LLC

Vinnitsa, , Ukraine

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Austria Bulgaria Canada Czechia France Germany Greece Hungary Israel Japan Netherlands South Africa South Korea Spain Ukraine

References

Explore related publications, articles, or registry entries linked to this study.

Panes J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 Jun;66(6):1049-1059. doi: 10.1136/gutjnl-2016-312735. Epub 2017 Feb 16.

Reference Type DERIVED
PMID: 28209624 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-001754-28

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

A3921084

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Open-Label Extension Study of GSK1605786A
NCT01318993 TERMINATED PHASE3